purpos
reviewatherosclerosi
lead
caus
death
global
pathophysiolog
atherosclerosi
fulli
understood
recent
studi
suggest
dipeptidyl
regul
inflamm
metabol
may
involv
develop
atherosclerot
diseas
recent
advanc
understand
function
atherosclerosi
discuss
review
recent
findingsmultipl
preclin
clinic
studi
suggest
axi
involv
develop
atherosclerot
diseas
howev
sever
recent
trial
assess
cardiovascular
effect
inhibit
indic
enzymat
inhibit
lack
benefici
effect
cardiovascular
diseas
summarycatalyt
inhibit
alter
pathway
could
favor
cardioprotect
aspect
function
may
contribut
overal
neutral
effect
cardiovascular
outcom
seen
outcom
trial
dipeptidyl
also
known
membran
glycoprotein
recent
gain
attent
owe
role
catalyt
degrad
incretin
review
summar
structur
function
known
role
cardiovascular
physiolog
atherosclerosi
provid
perspect
clinic
trial
inhibit
review
recent
data
mechanist
studi
outcom
driven
trial
transmembran
glycoprotein
dipeptidas
cleav
ntermin
dipeptid
protein
prolin
alanin
penultim
posit
highli
conserv
among
speci
form
homodim
tetram
plasma
membran
ntermin
cytoplasm
domain
transmembran
domain
larg
ctermin
extracellular
domain
figur
extracellular
domain
contain
domain
eightblad
domain
respons
dipeptidas
function
bind
protein
adenosin
deaminas
ada
fibronectin
wide
express
particularli
endothelium
epithelium
immun
cell
popul
extracellular
domain
may
cleav
circul
plasma
contribut
plasma
activ
activ
concentr
correl
type
diabet
atherosclerosi
bone
marrow
contribut
solubl
substanti
nearli
solubl
origin
bone
marrow
experiment
model
regul
express
fulli
understood
definit
evid
regul
inflammatori
mediat
promot
region
also
contain
ga
interferon
gammaactiv
sequenc
motif
bind
site
activ
interferon
retino
acid
lead
bind
ga
motif
transcript
enhanc
translat
transcript
activ
lymphocyt
decreas
express
suggest
translat
transloc
regul
cytokin
also
shown
upregul
express
incretin
peptid
glucagonlik
gastric
inhibitori
polypeptid
gip
respons
modul
postprandi
blood
glucos
promot
insulin
secret
pancreat
cell
via
glucagonostat
effect
gip
rapidli
inactiv
lead
short
halflif
minut
gip
mice
lack
protect
develop
dietinduc
obes
demonstr
improv
postprandi
glucos
control
pharmacolog
inhibit
enzymat
activ
improv
glucos
toler
wildtyp
mice
inhibit
also
improv
glycem
control
mice
suggest
addit
mechan
inhibitionmedi
antihyperglycem
effect
addit
incretin
peptid
also
cleav
number
protein
physiolog
target
includ
brain
natriuret
peptid
bnp
peptid
yy
stromalcellderiv
erythropoietin
granulocyt
coloni
stimul
factor
gcsf
substanc
p
catalyt
activ
extens
review
discuss
detail
stromal
deriv
physiolog
target
serv
chemoattract
bone
marrow
stem
cell
hematopoiet
stemprogenitor
cell
endotheli
progenitor
cell
epc
mesenchym
stem
cell
endogen
cardiac
stem
cell
cognat
receptor
preserv
inhibit
shown
promot
stem
cell
repopul
home
ischem
tissu
level
increas
plasma
ischem
tissu
shortli
ischem
injuri
respons
hypoxia
turn
regul
upregul
bind
promot
diseas
state
diabet
associ
upregul
may
repres
condit
associ
defect
home
integr
epc
owe
rapid
degrad
plasma
ischem
heart
tissu
improv
epc
number
endotheli
nitric
oxid
synthas
express
inhibit
previous
demonstr
thu
inhibitor
may
abil
enhanc
respons
may
improv
mediat
stem
cell
home
postmyocardi
infarct
howev
remain
test
human
signific
correl
observ
type
diabet
subject
also
demonstr
higher
activ
control
impair
glucos
toler
known
play
role
tcell
activ
function
modul
antigen
present
cell
function
activ
antibodi
recognit
adabind
epitop
enhanc
cell
activ
prolifer
cytokin
product
crosslink
antibodi
induc
tyrosin
phosphoryl
signal
molecul
downstream
cell
upon
bind
plasma
membran
protein
phosphoryl
result
phosphoryl
activ
nfkappa
b
interact
report
involv
pathogenesi
arthriti
could
import
atherosclerosi
bind
compon
extracellular
matrix
collagen
fibronectin
interact
potenti
play
role
sequestr
matrix
remodel
also
shown
independ
modul
inflamm
via
activ
effect
could
inhibit
via
silenc
proteas
activ
suggest
novel
role
proinflammatori
role
solubl
fraction
interact
ada
may
facilit
cell
activ
provid
suitabl
microenviron
cell
prolifer
anchor
ada
cell
surfac
modul
pericellular
adenosin
thu
regul
cell
activ
recent
demonstr
express
adipos
tissu
macrophag
also
involv
adipos
inflamm
insulin
resist
interact
ada
express
adipos
tissu
macrophag
higher
circul
increas
obes
insulin
resist
patient
antigen
present
cell
includ
macrophag
dendrit
cell
facilit
cell
prolifer
activ
noncatalyt
activ
catalyt
inhibit
addit
exogen
affect
capabl
stimul
cell
antigen
present
cellexpress
abl
bind
ada
promot
cell
activ
via
remov
suppress
effect
adenosin
earli
studi
found
express
atherosclerot
plaqu
associ
cell
level
express
correl
acut
coronari
syndrom
present
circul
activ
report
increas
patient
obes
posit
correl
level
degre
obes
measur
insulin
resist
inflamm
current
four
gliptin
approv
fda
sever
other
avail
europejapankorea
tabl
may
broadli
divid
two
class
base
structur
peptid
mimet
nonpeptidomimet
gliptin
select
inhibit
enzymat
activ
nm
sitagliptin
nm
vildagliptin
nm
saxagliptin
nm
alogliptin
nm
linagliptin
interfer
member
dpp
famili
includ
continu
inhibit
plasma
activ
note
approv
agent
even
hour
weekli
inhibitor
provid
durabl
control
although
effect
appear
modest
could
import
diabet
prevent
standpoint
potenti
util
prediabet
glycemia
lower
efficaci
roughli
compar
may
rang
decreas
substanti
differ
individu
respons
note
good
evid
inhibit
mediat
cardiovascular
protect
effect
model
myocardi
infarct
atherosclerosi
heart
failur
express
post
infarct
heart
higher
level
particularli
border
zone
well
fail
heart
express
activ
posit
associ
bodi
weight
adult
dog
significantli
higher
degre
heart
failur
surviv
rate
infarct
size
significantli
improv
mice
lad
ligat
accompani
enhanc
express
prosurviv
signal
pathway
pakt
atrial
natriuret
peptid
cardiac
tissu
pharmacolog
inhibit
sitagliptin
enhanc
express
cardioprotect
protein
improv
function
recoveri
ischemiareperfus
injuri
murin
heart
pharmacolog
genet
inhibit
revers
diabet
diastol
left
ventricular
dysfunct
fibrosi
pressureoverloadinduc
left
ventricular
dysfunct
mice
number
effect
induct
prosurviv
pathway
seen
respons
inhibit
postul
occur
via
activ
signal
engag
g
proteincoupl
receptor
lead
activ
adenyl
cyclas
stimulatori
gs
subunit
subsequ
accumul
camp
least
classic
organ
beta
cell
howev
mechan
via
degrad
product
also
suggest
mice
limit
infarct
size
promot
cardiomyocyt
surviv
ischaemiareperfus
injuri
activ
k
signal
pathway
suggest
exist
differ
receptor
abl
bind
cleav
form
mulvihil
et
al
recent
report
substanti
differ
genet
defici
result
cardioprotect
phenotyp
character
reduct
lvh
improv
lv
eject
fraction
function
indic
improv
exercis
toler
mice
follow
transvers
aortic
constrict
associ
reduc
fibrosi
paradox
upregul
marker
inflamm
contrast
pharmacolog
inhibit
result
impair
cardiac
function
cardiac
hypertrophi
suggest
enzymat
inhibit
alon
may
suffici
reduc
cardiac
fibrosi
addit
drugrel
nonspecif
effect
rule
result
also
differ
result
paper
pharmacolog
inhibit
sitagliptin
alogliptin
shown
protect
studi
may
reflect
differ
model
diabet
strain
suscept
differenti
impact
diet
import
consid
mice
model
global
defici
repres
catalyt
inactiv
occur
pharmacolog
model
inhibit
differ
structur
mous
human
may
result
differ
ada
bind
may
substanti
implic
translat
find
anim
model
human
open
label
studi
patient
exist
coronari
arteri
diseas
undergo
dobutamin
stress
echocardiographi
protect
ischemia
induc
alter
left
ventricular
function
peak
systol
veloc
observ
human
inhibit
suggest
acut
cardioprotect
ischemia
induc
contractil
dysfunct
presumagbl
relat
elev
sitagliptin
singl
dose
week
treatment
doubl
blind
long
term
studi
vildagliptin
ventricular
dysfunct
diabet
vividd
patient
heart
failur
reduc
eject
fraction
although
differ
left
ventricular
eject
fraction
follow
year
treatment
increas
left
ventricular
enddiastol
volum
report
patient
random
vildagliptin
interestingli
improv
note
ntbnp
level
studi
studi
collect
indic
complex
effect
catalyt
inhibit
difficult
reconcil
readili
certainli
possibl
substanti
differ
individu
inhibitor
need
entertain
result
inhibit
endotheli
function
inconsist
part
variabl
may
reflect
differ
protocol
includ
methodolog
measur
endotheli
function
notori
difficult
replic
often
differ
patient
patient
treatment
vildagliptin
week
patient
type
diabet
improv
forearm
blood
vasodil
respons
intraarteri
administ
acetylcholin
sodium
nitroprussid
sitagliptin
treatment
week
significantli
improv
flowmedi
dilat
diabet
patient
uncontrol
sulfonylurea
metformin
pioglitazon
treatment
contrast
anoth
studi
demonstr
flowmedi
dilat
suppress
sitagliptin
alogliptin
recent
studi
acut
inhibit
potenti
vasodilatori
respons
infus
bnp
healthi
subject
signific
find
applic
diabet
long
term
inhibitor
remain
question
inhibitor
unlik
agonist
appear
blood
pressur
lower
effect
blood
pressur
lower
effect
agonist
attribut
direct
vasorelax
effect
natriuret
mechan
central
nervou
system
mechan
reason
lack
bp
lower
effect
inhibit
may
simpli
relat
magnitud
elev
compar
pharmacolog
strategi
agon
anoth
mechan
rais
condit
high
peptid
yy
convert
peptid
yy
activ
receptor
may
potenti
angiotensin
ii
signal
definit
data
support
human
howev
lack
lipoprotein
effect
agonist
also
review
detail
prior
review
although
prior
small
studi
examin
effect
postprandi
lipid
shown
reduct
vldl
remnant
lipoprotein
effect
thought
larg
occur
via
mediat
reduct
absorpt
triglycerid
synthesi
lipoprotein
limit
studi
one
doubl
blind
conduct
week
doubl
blind
studi
show
reduct
postprandi
triglycerid
chylomicron
respect
remain
studi
shortterm
effect
note
occur
even
singl
dose
independ
weight
loss
multipl
studi
demonstr
efficaci
reduc
atherosclerosi
anim
includ
rodent
rabbit
longterm
studi
involv
inhibit
alogliptin
reduc
atherosclerot
plaqu
vascular
inflamm
note
highfat
fed
atherosclerosi
prone
ldlr
mice
reduct
plaqu
associ
reduct
inflamm
monocytemacrophag
activ
chemotaxi
reduc
macrophag
foam
cell
format
smooth
muscl
prolifer
macrophag
polar
toward
phenotyp
suggest
mechan
inhibitioninduc
improv
atherosclerosi
recent
human
studi
alogliptin
shown
reduc
carotid
intimamedia
thick
patient
free
histori
appar
cardiovascular
diseas
extent
find
help
explain
find
clinic
trial
determin
appropri
long
term
durat
studi
human
longer
current
year
trial
horizon
cardiovascular
safeti
trial
note
three
larg
random
doubleblind
placebo
control
clinic
trial
evalu
hard
cardiovascular
endpoint
tabl
primari
motiv
trial
safeti
base
prior
fda
direct
provid
safeti
data
prior
certain
instanc
follow
regulatori
approv
three
complet
trial
met
primari
object
exclud
unaccept
level
ischem
cardiovascular
risk
defin
fda
guidanc
trial
savortimi
examin
efficaci
endpoint
composit
cv
death
nonfat
myocardi
infarct
nonfat
stroke
efficaci
endpoint
teco
also
includ
hospit
unstabl
angina
savortimi
test
saxagliptin
mg
qd
mg
mlmin
versu
placebo
patient
establish
cv
diseas
patient
major
risk
factor
approxim
month
studi
design
superior
trial
prespecifi
noninferior
comparison
saxagliptin
superior
placebo
hr
confid
interv
p
met
noninferior
criterion
examin
random
doubl
blind
placebocontrol
noninferior
studi
alogliptin
mg
qd
gfr
mlmin
versu
placebo
diabet
acut
coronari
syndrom
major
composit
endpoint
similar
alogliptin
placebo
hr
upper
boundari
onesid
repeat
confid
interv
p
noninferior
teco
assess
effect
sitagliptin
mg
mg
gfr
mlmin
daili
diabet
histori
cv
diseas
primari
endpoint
ident
two
group
trial
meet
criterion
noninferior
vs
hr
confid
interv
p
noninferior
import
consider
antidiabet
agent
cardiovascular
benefit
cv
benefit
seen
within
durat
year
current
design
studi
howev
possibl
delay
benefit
may
still
occur
besid
cardiovascular
benefit
cost
treatment
burden
advers
effect
therapi
diabet
overarch
consider
treatment
burden
advers
effect
appreci
neg
impact
patient
qualiti
life
prior
studi
show
intervent
high
treatment
burden
treat
glucos
glycem
disutil
may
substanti
attenu
benefit
measur
qualiti
adjust
life
year
health
econom
analys
suggest
may
incur
signific
cost
upfront
improv
sideeffect
profil
compar
convent
therapi
diabet
may
substanti
instanc
rel
glyburid
secondlin
therapi
use
incretin
agent
associ
addit
qualityadjust
life
year
per
patient
result
compar
benefit
accru
number
highlyeffect
prevent
treatment
strategi
heart
failurean
unexpect
find
savortimi
increas
incid
heart
failur
hf
hospit
prespecifi
endpoint
saxagliptin
compar
placebo
vs
hr
confid
interv
without
excess
heart
failur
relat
mortal
previou
hf
egfr
mlm
elev
bnp
albumincreatinin
ratio
strongest
predictor
heart
failur
hospit
excess
heart
failur
risk
note
alogliptin
lixisenatid
highrisk
ac
patient
popul
assuag
concern
examin
first
occurr
hospit
hf
occur
alogliptin
placebo
group
respect
confid
interv
excess
cardiovascular
death
teco
hospit
rate
hf
ident
sitagliptin
placebo
vs
hr
develop
specif
highlight
pathophysiolog
import
atherosclerosi
cardiac
remodel
associ
diabet
diabet
heart
failur
although
catalyt
inhibit
clearli
alter
pathway
could
favor
cardioprotect
mani
question
remain
regard
role
pathogenesi
atherosclerosi
aspect
function
may
help
reconcil
differ
result
note
pharmacolog
inhibit
defici
knock
model
mulvihil
et
al
recent
report
treatment
inhibitor
result
modest
cardiac
hypertrophi
impair
cardiac
function
diabet
mice
agonist
defici
improv
cardiac
function
result
suggest
either
action
inhibit
drugrel
unspecif
effect
may
contribut
cardiac
dysfunct
human
short
term
long
term
use
safe
cardiovascular
perspect
lack
efficaci
cv
perspect
rais
import
defici
agent
must
contextu
fact
durat
larg
outcom
trial
shorter
year
inhibitor
safe
cardiovascular
standpoint
inhibitor
improv
cardiovascular
outcom
patient
durat
less
year
multipl
studi
suggest
catalyt
inhibit
alter
pathway
could
favor
cardioprotect
saxagliptin
increas
hospit
rate
heart
failur
compar
placebo
inhibitor
includ
alogliptin
sitagliptin
affect
heart
failur
hospit
rate
aspect
function
may
contribut
overal
neutral
effect
cardiovascular
outcom
seen
outcom
trial
